Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?

• Published in: Cancers Vol. 16; no. 17; p. 3072
• Main Authors: Ahari, Daniel, Wilkinson, Mark, Ali, Nisha, Taxiarchi, Vicky P., Dave, Rajiv V., Gandhi, Ashu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.09.2024
• Subjects: Audit departments; Biopsy; Breast cancer; Breast surgery; Cancer therapies; Cell cycle; Cyclin-dependent kinases; Epidermal growth factor; Estrogens; Kinases; Lymphatic system; Lymphedema; Metastases; Morbidity; Nodes; Patients; Surgery; Womens health; axillary node clearance; monarchE study; CDK4/6 inhibitors; abemaciclib

The monarchE study added the CDK4/6 inhibitor abemaciclib to the care of women with oestrogen-positive (ER+) breast cancers. Eligibility required meeting monarchE criteria—either >3 positive axillary nodes, or 1–3 positive sentinel nodes (SNB+) with tumour size >50 mm or grade 3 cancers. Women...